ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogs
Guiqiang Wang(Qinghai University), Jinzi J. Wu(Bioscience Research), Jiajie Lu(Sichuan University), Jinlin Hou(Southern Medical University), Guoxin Hu(Wenzhou Medical University), Ye Gu(The Sixth People's Hospital of Shenyang), Yongfeng Yang(Shenyang Agricultural University), Yimin Cui(Peking University), Qin Zhang(Novartis (Switzerland)), Lei Fu(Central South University), Yong‐Ping Chen(Jacobson Holman (United States)), Xinyue Chen(Sichuan University), Xiaolin Guo(Peking University), Yao Xie(Capital Medical University), Qianguo Mao(Army Medical University), Handan He, Yue-Mei Yan(Beijing Children’s Hospital), Qing Xie(University of Southern California), Guizhou Zou(Anhui Medical University)
Cited by 20
Related Papers
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)
|Journal of Clinical and Translational Hepatology|2017|277
Developing a dengue forecast model using machine learning: A case study in China
|PLoS neglected tropical diseases|2017|270